Drug sensitivity and resistance genes in cancer chemotherapy: A chemogenomics approach

Drug Discovery Today

Volumn 8, Issue 8, 2003, Pages 356-363

  Huang, Ying ^a   Sadée, Wolfgang ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; DOXORUBICIN; FLUOROURACIL; MESSENGER RNA;

CANCER CHEMOTHERAPY; CANCER GENETICS; CHEMOSENSITIVITY; DNA MICROARRAY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; GENE IDENTIFICATION; GENOMICS; HUMAN; PHARMACOGENOMICS; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENOME, HUMAN; HUMANS; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOMICS; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037446295     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02654-0     Document Type: Review

References (41)

1. Gottesman M.M., et al. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer. 2:2002;48-58.
2. Bleicher K.H. Chemogenomics: bridging a drug discovery gap. Curr. Med. Chem. 9:2002;2077-2084.
3. Lipshutz R.J., et al. High density synthetic oligonucleotide arrays. Nat. Genet. 21:(Suppl. 1):1999;20-24.
4. DeRisi J., et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 14:1996;457-460.
5. Scherf U., et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24:2000;236-244.
6. Staunton J.E., et al. Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. U. S. A. 98:2001;10787-10792.
7. Butte A.J., et al. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc. Natl. Acad. Sci. U. S. A. 97:2000;12182-12186.
8. Bao L., et al. Mining functional relationships in feature subspaces from gene expression profiles and drug activity profiles. FEBS Lett. 516:2002;113-118.
9. Wallqvist A., et al. Establishing connections between microarray expression data and chemotherapeutic cancer pharmacology. Mol. Cancer Ther. 1:2002;311-320.
10. Dan S., et al. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 62:2002;1139-1147.
11. Moriyama M., et al. Relevance network between chemosensitivity and transcriptome in human hepatoma cells. Mol. Cancer Ther. 2:2003;199-205.
12. Lage H., et al. Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS lett. 503:2001;179-184.
13. Kudoh K., et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60:2000;4161-4166.
14. Watts G.S., et al. cDNA microarray analysis of multidrug resistance: doxorubicin selection produces multiple defects in apoptosis signaling pathways. J. Pharmacol. Exp. Ther. 299:2001;434-441.
15. Wittig R., et al. Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res. 62:2002;6698-6705.
16. Zembutsu H., et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 62:2002;518-527.
17. Kihara C., et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 61:2001;6474-6479.
18. Sotiriou C., et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 4:2002;1-8.
19. Ramaswamy S., et al. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 33:2003;49-54.
20. van' t Veer L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
21. Alizadeh A.A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:2000;503-511.
22. Beer D.G., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8:2002;816-824.
23. Rosenwald A., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl. J. Med. 346:2002;1937-1947.
24. Benderra Z., et al. Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein. Int. J. Oncol. 12:1998;711-715.
25. Anderson L., Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis. 18:1997;533-537.
26. Gygi S.P., et al. Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19:1999;1720-1730.
27. Kononen J., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4:1998;844-847.
28. Bubendorf L., et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J. Natl. Cancer Inst. 91:1999;1758-1764.
29. Moch H., et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol. 154:1999;981-986.
30. Sallinen S.L., et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 60:2000;6617-6622.
31. Huang Y., et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc. Natl. Acad. Sci. U. S. A. 98:2001;15044-15049.
32. Sandusky G.E., et al. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology. 41:2002;65-74.
33. Verma M., et al. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann. New York Acad. Sci. 945:2001;103-115.
34. Wu W., et al. Proteomics in cancer research. Int. J. Gynecol. Cancer. 12:2002;409-423.
35. Sinha P., et al. Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J. Biochem. Biophys. Methods. 37:1998;105-116.
36. Sinha P., et al. Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis. 20:1999;2952-2960.
37. Sinha P., et al. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis. 20:1999;2961-2969.
38. Sinha P., et al. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis. 21:2000;3048-3057.
39. Poland J., et al. Study of therapy resistance in cancer cells with functional proteome analysis. Clin. Chem. Lab. Med. 40:2002;221-234.
40. Chen S.T., et al. Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett. 181:2002;95-107.
41. Blower P.E., et al. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J. 2:2002;259-271.